Gilead Sciences (Australia)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (Australia), Australia, covering academic research published from 2002 to 2024. Read More.
Open Access Percentage
65%
Total
Publications
84
Total Open
Publications
55
Total
Citations
3.9K
Open Access
Percentage
65%
Total
Publications
84
Total Open
Publications
55
Total
Citations
3.9K
Breakdown
Publisher Open
23%
Both
35%
Other Platform Open
8%
Closed
34%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 37%
18
Hybrid 23%
11
No Guarantees 40%
19
Other Platform Open
Domain 89%
32
Institution 22%
8
Public 11%
4
Other Internet 8%
3
Preprint 6%
2
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 31 |
Europe PMC | Domain | 20 |
University of Bristol - Bristol Research | Institution | 4 |
Semantic Scholar | Public | 4 |
Le Centre pour la Communication Scientifique Directe - HAL - Université Paris Descartes | Institution | 2 |
University of Zurich - Zurich Open Repository and Archive | Institution | 1 |
University of Modena and Reggio Emilia - IRIS UNIMORE | Institution | 1 |
University of California - eScholarship University of California | Institution | 1 |
Universitat de Barcelona - Dipòsit Digital de la Universitat de Barcelona | Institution | 1 |
Universitat Autònoma de Barcelona - Dipòsit Digital de Documents de la UAB | Institution | 1 |